Trial Profile
Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Rucaparib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 02 Mar 2021 Status changed from recruiting to completed.
- 22 Aug 2020 Planned End Date changed from 30 Dec 2020 to 31 Aug 2022.
- 22 Aug 2020 Planned primary completion date changed from 1 Sep 2020 to 31 Aug 2022.